Neural Regeneration Research ›› 2023, Vol. 18 ›› Issue (6): 1243-1248.doi: 10.4103/1673-5374.358615

Previous Articles     Next Articles

Long-noncoding RNAs as epigenetic regulators in neurodegenerative diseases

Paola Ruffo1, Francesca De Amicis2, Emiliano Giardina3, 4, Francesca Luisa Conforti1, *   

  1. 1Medical Genetics Laboratory, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy;  2Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy;  3Genomic Medicine Laboratory UILDM, IRCCS Fondazione Santa Lucia, Rome, Italy;  4Department of Biomedicine & Prevention, Tor Vergata University of Rome, Rome, Italy
  • Online:2023-06-15 Published:2022-12-22
  • Contact: Francesca Luisa Conforti, PhD, francescaluisa.conforti@unical.it.
  • Supported by:
    This work was funded by a special award to the Department of Pharmacy, Health and Nutritional Sciences of University of Calabria (Italy) (Department of Excellence, Italian Law232/2016) from the Italian Ministry of Research and University (MIUR) to FLC.

Abstract: The growing and rapid development of high-throughput sequencing technologies have allowed a greater understanding of the mechanisms underlying gene expression regulation. Editing the epigenome and epitranscriptome directs the fate of the transcript influencing the functional outcome of each mRNA. In this context, non-coding RNAs play a decisive role in addressing the expression regulation at the gene and chromosomal levels. Long-noncoding RNAs, consisting of more than 200 nucleotides, have been shown to act as epigenetic regulators in several key molecular processes involving neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and Huntington’s disease. Long-noncoding RNAs are abundantly expressed in the central nervous system, suggesting that their deregulation could trigger neuronal degeneration through RNA modifications. The evaluation of their diagnostic significance and therapeutic potential could lead to new treatments for these diseases for which there is no cure.

Key words: Alzheimer’s disease, amyotrophic lateral sclerosis, epigenetic mechanism, Huntington’s disease, long-noncoding RNAs, neurodegenerative disease, non-coding RNAs, Parkinson’s disease